(Country; Symbol)


Type Of

Product Area

Details (Date)


University of Chicago; Baylor College of Medicine; the University of California, Davis; and the Institute of Enzymology in Budapest

Collaboration agreement

Drug targets for central nervous system diseases and obesity

AGY's imAGYne platform technology will be used in all four collaborations (6/28)

AlphaGene Inc.*

Lahey Clinic


Molecular genetics of prostate cancer

Parties will study the molecular genetics of prostate cancer and investigate the role of prostate-specific carcinoembryonic antigen as a diagnostic and prognostic market (7/11)

AM Pharma BV
(the Netherlands)*

Leiden University Medical Center

Licensing and development agreement

Diagnostic test to distinguish infection from sterile inflammation

The diagnostic will be based on human peptides that are able to bind at bacteria and fungi at sites of infection (8/15**)

Antigenics Inc.

Bruce Walker, director of the Partners AIDS Research Center at Massachusetts General Hospital


HIV-related antigens and heat shock protein technology

The collaboration will involve a study combining work in identifying HIV-related antigens and Antigenics' heat shock protein technology (7/25)

Aphios Corp.*

National Cancer Institute


Process for the extraction and purification of potential anticancer, natural product drugs

The drugs will come from a variety of plant, marine organism and microbial sources (7/17)


National Jewish Medical and Research Center

Exclusive licensing agreement

Therapeutics to treat inflammation

Agreement is to develop therapeutics based on MEK kinases and related technology to treat inflammation (7/12)

Atlantic Technology Ventures Inc. (ATLC)

Christopher Vaughan, senior scientist at the Pain Management and Research Center of the University of Sydney

Research collaboration


Collaboration will work to find the synergistic effects of opioids and cannabinoids, specifically CT-3 (5/29)


Loma Linda University Medical Center

License agreement

New technology covered under patent rights for "Iron Regulating Protein-2 as a Diagnostic for Alzheimer's Disease and Other Neuro- degenerative Diseases"

The agreement gives BioErgonomics an option to acquire an exclusive license to commercialize certain new technology covered under the center's patent rights (7/19)

Caliper Technologies Corp. (CALP)

National Aeronautics and Space Administration

Program collaboration through a subcontract

Macromolecular crystals

Caliper and the administration established an applications developer program collaboration through a subcontract with Sverdrup Technology Inc., to create macromolecular crystals aboard the International Space Station using LabChip technology (7/23)


National Cancer Institute

Subscription agreement

Celera's databases and tools

Individual NCI principal investigators may elect whether or not to purchase access to Celera's analytical tools and database products, including the fruit fly, human and mouse genomes (7/9)


Netherlands Organization for Scientific Research

Multiyear subscription

Celera's genomic databases and bio- informatics expertise

The NWO plans to use the subscription to facilitate access to genomics data for the Dutch research community (7/3)


University of Alabama at Birmingham, Case Western Reserve University School of Medicine, the Fred Hutchinson Cancer Research Center, University of Oxford and Pennington Biomedical Research Center

Multiyear agreements

Celera's database products

The agreements allow the institutions to access Celera's database products, using the company's Discovery system (7/19)

Cepheid Inc.

University of Pittsburgh


Genetic tests for use during surgery to determine whether cancer has spread

In the three-year collaboration, researchers will identify and evaluate new genetic markers for several cancers, including lung, breast, esophagus, oral, head and neck cancer and melanoma; Cepheid's Smart Cycler will be used to validate these markers for detection of cancer in lymph nodes (8/6)

CombiMatrix Corp. (subsidiary of Acacia Research Corp.; ACRI)

NASA Ames Research Center

License and supply agreement

Active biochips and related technology

The agreement provides for the license, purchase and use by NASA of CombiMatrix's active biochips and related technology to conduct biological research both on earth and in space (8/8)

Compugen Ltd.
(Israel; CGEN)

Albert Einstein College of Medicine of Yeshiva University and the Weizmann Institute of Science

Access agreements


Compugen will provide Gencarta, its annotated genome, transcriptome and proteome database to the college and institute (7/23)

Corixa Corp.

Space and Naval Warfare Systems Center San Diego

Contract agreement

Methods of enhancing immune responses to infectious diseases, including agents of biological warfare

Agreement is a $3.5M, two-year contract in which Corixa will conduct preclinical testing of its portfolio of synthetic lipid A-like immunomodulatory agents (6/12)

Cray Inc.

National Cancer Institute


Bioinformatics research tools

The aim is to develop genome analysis software designed to identify and analyze genes involved in cancer and other diseases (7/9)

Curacyte AG (Germany)*

Friederich Shiller University

Property rights agreement

Small-molecule factor Xa inhibitors

Curacyte acquired the rights and it will initiate a research collaboration with the Center for Vascular Biology and Medicine of the University of Jena in order to identify an oral inhibitor of factor Xa (6/19)

Diatos SA (France)*

Universite Catholique de Louvain (Belgium)

Research and development collaboration

Tumor-activated prodrugs and drug delivery systems

Collaboration will bring the parties' technologies together (6/5)

EntreMed Inc. (ENMD)

National Eye Institute

Two-year cooperative research and development agreement


Parties will study the role that Panzem can play in treating the retinal angiogenesis that leads to age-related macular degeneration (6/25)

Forbes Medi-Tech Inc. (Canada; FMT; TSE:FMII)

University of British Columbia

Collaborative research agreement

FM-VP4, and related compounds

Parties were awarded a $280,000 grant to study the mechanism of action of sterol-based pharma- ceuticals on cholesterol absorption (8/13)

Genencor International

Centre for Applied Microbiology & Research (UK)

Technology development collaboration

Technology to eliminate prions, the infectious agents that cause mad cow disease and its human form, Creutzfeld- Jakob disease

The two-year collaboration is focused on an enzyme-based process for treating surgical equipment, rendered animal material and blood products to eliminate prion infectivity (8/2)

Genetix Group plc (UK; LSE:GTX)

University of Hertfordshire

Exclusive rights agreement

Computer software

Genetix acquired rights to the software for the identification and analysis of genes linked to disease (6/21)

GlycoDesign Inc. (Canada; TSE:GD)

Brigham and Women's Hospital of Boston

Research collaboration


The research involves a form of CD44 found on human bone marrow stem cells; the goal of the research is to develop reagents that can be used to treat patients with blood diseases and improve the recovery of patients following bone marrow transplants (8/13)

Helix BioMedix Inc. (Canada; HXBM)

University of British Columbia

Exclusive license agreement

Classes of peptides

Helix acquires the rights to several distinct classes of peptides that have demonstrated efficacy in animal models (8/6)

Hemispherx Biopharma Inc. (AMEX:HEB)

The Orange County Center for Special Immunology

Research agreement

A new approach to treating HIV infection

Company will begin a research trial with the center; the study will use immune-based therapy with Ampligen in combination with strategic therapeutic interruptions of antiviral medications (6/7)

ILEX Oncology Inc. (ILXO)

Dana-Farber Cancer Institute

License agreement

MUC1 protein patents

Company entered a worldwide, exclusive license agreement for patent rights and technology related to the MUC1 protein (7/26)

Incyte Genomics Inc. (INCY)

Guy's and St. Thomas' Hospital NHS Trust (UK)


Genomic research of osteoarthritis

Incyte will own the intellectual property resulting from the collaboration (8/14)

InforMax Inc.

Windber Research Institute

License agreement

GenoMax enterprise software system

The agreement includes a software license, system support and professional services (7/31)

Inc. (INGN)

University of California

Research agreement

Gene therapy to treat rheumatoid arthritis

Parties will evaluate the potential use of gene therapy in preclinical studies (6/5)


University of California, San Diego


Computational tools

Parties will conduct research to develop computational tools to identify and decipher the function of mitochondrial proteins (7/10)

Orchid BioSciences Inc.'s Cellmark Diagnostics business unit (ORCH)

UK government


Genotyping services

The genotyping services are designed to help British farmers breed sheep with reduced susceptibility to the disease scrapie (8/8)

Prometic Life Sciences Inc. (Canada; TSE:PLI)

American Red Cross

Agreement to form new company

Transmissible spongiform encephalopathy (TSE)

Parties will form a new company to use Prometic's platform technology and the ARC's expertise in TSE research and pathogen clearance in blood products (7/3)

Pyrosequencing AB (Sweden; SSE:PYRO)

The Children's Hospital of Philadelphia

Research agreement

Genes linked to hearing loss

Collaboration will analyze genes linked to hearing loss and will develop diagnostic tests using Pyrosequencing technology (6/18)

Quark Biotech Inc.*

Cleveland Clinic Foundation

Multiyear research collaboration


Collaboration will work toward developing a powerful genomic technology for use in the humanization of monoclonal antibodies (5/31)

RheoGene LLC*

Stanford University

Exclusive licensing agreement

U.S. Patent No. 6,245,531

Patent covers genes that encode insect-based ecdysone receptors and methods for regulating gene expression in host cells (6/20)

Samaritan Pharmaceuticals Inc. (OTC BB:SPHC)

Georgetown University

Seven-year research collaboration

One-molecule drugs and a diagnostic for Alzheimer's disease

Collaboration also will focus on new drug development in oncology and neurology; Samaritan receives worldwide exclusive rights to any therapeutic agents or diagnostic technologies; Samaritan will pay research costs and Georgetown will receive warrants to buy 500,000 shares of Samaritan's stock at $1.50 per share, as well as potential royalty payments (6/12)

SurroMed Inc.*

Palo Alto Medical Foundation

Exclusive multiyear research collaboration

Biological marker discovery and comprehensive diseases phenotyping

Collaboration will initially focus on rheumatoid arthritis (6/5)

Vasogen Inc.
(Canada; AMEX: MEW)

Canadian Network for Vaccines and Immuno- therapeutics

Research collaboration

Immune modulation therapy

Collaboration will focus on the development of Vasogen's immune modulation therapy (6/12)

Waratah Pharmaceuticals Inc. (Canada; CDNX:WAR)

Muttart Diabetes Center at the University of Alberta Medical Center

Collaborative research agreement

I.N.T. growth factors

The collaboration coincides with a Waratah presentation of efficacy results demonstrating that a 10-day treatment of diabetic rats improved glucose tolerance for at least four months; the collaboration will seek to confirm the finding (6/27)


This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange